Affinity Asset Advisors LLC Has $5.26 Million Holdings in Viridian Therapeutics, Inc. $VRDN

Key Points

• Affinity Asset Advisors LLC increased its stake in Viridian Therapeutics by 144.3% during the first quarter, owning approximately $5.26 million worth of the company's stock.
• Multiple analysts have recently issued ratings on Viridian, with Jefferies Financial Group assigning a "buy" rating and a price target of $44.00, while the overall consensus rating is a "Moderate Buy" with an average target price of $37.78.
• Viridian Therapeutics reported earnings of ($1.00) per share, aligning with analysts' estimates, and indicated a 4.2% increase in revenue compared to the same quarter last year.

Affinity Asset Advisors LLC lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 144.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 390,000 shares of the company's stock after acquiring an additional 230,386 shares during the quarter. Affinity Asset Advisors LLC owned about 0.48% of Viridian Therapeutics worth $5,257,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in VRDN. Price T Rowe Associates Inc. MD lifted its position in shares of Viridian Therapeutics by 2,847.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock worth $25,436,000 after purchasing an additional 1,281,799 shares during the last quarter. Deep Track Capital LP lifted its position in shares of Viridian Therapeutics by 20.6% during the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after purchasing an additional 771,796 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in shares of Viridian Therapeutics by 155.9% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock worth $20,850,000 after purchasing an additional 662,634 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Viridian Therapeutics by 198.2% during the 4th quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock worth $13,055,000 after purchasing an additional 452,627 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of Viridian Therapeutics by 579.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 362,893 shares of the company's stock worth $4,892,000 after purchasing an additional 309,518 shares during the last quarter.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.12 during trading hours on Thursday, hitting $18.44. The stock had a trading volume of 485,387 shares, compared to its average volume of 874,275. The company has a 50-day moving average of $16.87 and a two-hundred day moving average of $15.15. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.51 billion, a PE ratio of -4.81 and a beta of 0.42. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The business had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.05 million. During the same period in the prior year, the firm posted ($0.81) EPS. Viridian Therapeutics's quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several research analyst reports. Royal Bank Of Canada cut their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. JMP Securities cut their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Oppenheimer boosted their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Needham & Company LLC cut their price objective on Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group upped their price target on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.78.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.